Short-Term Outcomes After Multisystem Inflammatory Syndrome in Children Treatment

Clouser, Katharine N.; Gadhavi, Jasmine; Bhavsar, Sejal Makvana; Lewis, Rachel; Ballance, Cathleen; Michalak, Zuzanna; Baer, Aryeh; Kriegel, Marni; Pall, Harpreet; Piwoz, Julia A; Slavin, Kevin; Siegel, Mark E; Tozzi, Meghan; Tozzi, Roberto; Walker, David M.; Lapidus, Sivia; Aschner, Judy L.

doi:10.1093/jpids/piaa151

Cited by 9 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data conforms to early studies' findings 17,23,24 that PIMS-TS is a short term, albeit sometimes severe illness with clinical resolution in under 6 months. Children and their parents therefore can be reassured that bowel inflammation rarely persists.…”

Section: N P R E S Ssupporting

confidence: 93%

Abdominal US in Pediatric Inflammatory Multisystem Syndrome Associated with SARS-CoV-2 (PIMS-TS)

et al. 2022

View full text Add to dashboard Cite

AbbreviationsCRP C-reactive protein MIS-C Multisystem inflammatory syndrome in children PIMS-TS Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 RCPCH The Royal College of Paediatrics and Child Health Key Results 1) In a retrospective review of 140 children with suspected pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS), abdominal symptoms were present in 95% with PIMS-TS as a single pathology.2) Of 102 children who underwent abdominal US at presentation, ascites was present in 64%, mesenteric inflammation in 16%, and bowel wall thickening in 14%.3) In 17 children with more than 2 months of follow up, bowel involvement and other US abnormalities resolved in all 17 patients.

show abstract

Section: N P R E S Ssupporting

confidence: 93%

Abdominal US in Pediatric Inflammatory Multisystem Syndrome Associated with SARS-CoV-2 (PIMS-TS)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…From the full‐text reading, 29 more studies were excluded because they did not fit the eligibility criteria. Thus, 50 studies were selected for review, 8–57 and 30 were included in the meta‐analysis (Figure 1). 8–37 …”

Section: Resultsmentioning

confidence: 99%

“…Thus, 50 studies were selected for review, 8–57 and 30 were included in the meta‐analysis (Figure 1). 8–37 …”

Section: Resultsmentioning

confidence: 99%

Cardiac manifestations in children with the multisystem inflammatory syndrome (MIS‐C) associated with SARS‐CoV‐2 infection: Systematic review and meta‐analysis

Arantes

Conegundes

Miranda

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

According to the World Health Organisation, as of October 2022, there have been 55,560,329 reported cases of SARS‐COV‐2 in patients under 19 years old. It is estimated that about 0.06% of these patients may develop MIS‐C, representing more than 2 million children worldwide. This systematic review and meta‐analysis examined the pooled prevalence of cardiovascular manifestation and cardiac complications in children hospitalised with MIS‐C. The PROSPERO register number is CRD42022327212. We included case‐report studies, case‐control studies, cohort studies, and cross‐sectional studies, as well as clinical trials or studies describing cardiac manifestations of MIS‐C and its sequelae in a paediatric population. Initially, 285 studies were selected, but there were 154 duplicates, and 81 were excluded because they did not fit the eligibility criteria. Thus, 50 studies were selected for review, and 30 were included in the meta‐analysis. A total sample size of 1445 children was included. The combined prevalence of myocarditis or pericarditis was 34.3% (95% CI: 25.0%–44.2%). The combined prevalence for echocardiogram anomalies was 40.8% (95% CI: 30.5%–51.5%), that of Kawasaki disease presentation was 14.8% (95% CI: 7.5%–23.7%), and that of coronary dilation was 15.2% (95% CI: 11.0%–19.8%). The rate of electrocardiogram anomalies was 5.3% (95% CI: 0.8%–12.3%), and the mortality rate was 0.5% (CI 95%: 0%–1.2%). Furthermore, 186 children still had complications at discharge, with a combined prevalence of such long‐lasting manifestations of 9.3% (95% CI: 5.6%–13.7%). Studies that assess whether these children will have an increased cardiovascular risk with a greater chance of acute myocardial infarction, arrhythmias, or thrombosis will be essential for healthcare planning.

show abstract

“…Furthermore, drug-induced liver damage should not be excluded. In a retrospective chart review of a cohort of children treated with a multidisciplinary approach and consensus-driven algorithm, the short-term outcomes of these patients were found to be generally favorable [ 9 ]. However, in existing literature on MIS-C, there are no data concerning the mid-long-term outcomes of these patients.…”

Section: Discussionmentioning

confidence: 99%

“…On 13 May 2020, the Center for Disease Control (CDC) issued a case definition specifying that the patient should be <21 years old, have fever, with laboratory evidence of inflammation (including, but not limited to, 1 or more of the following: an elevated CRP, erythrocyte sedimentation rate, fibrinogen, procalcitonin, D-dimer, ferritin, lactate dehydrogenase, IL-6, elevated neutrophils, reduced lymphocytes and low albumin level), and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, haematological, gastrointestinal, dermatological or neurological), in the absence of an alternative plausible diagnosis, as well as evidence of SARS-CoV-2 infection or exposure [ 8 ]. In existing pediatric literature on MIS-C, only short-term outcomes were reported [ 9 ], as there are currently no published reports detailing long term outcomes in these patients.…”

Section: Introductionmentioning

confidence: 99%

New Onset of Hepatic Steatosis Post-Severe Multisystem Inflammatory Syndrome in Children (MIS-C): A Case Report

Sica¹,

Pennoni²,

Penta³

et al. 2021

IJERPH

View full text Add to dashboard Cite

The emergence of Multisystem Inflammatory Syndrome (MIS-C) following SARS-CoV-2 infection in children and adolescents provided a new diagnostic and management challenge as there is limited knowledge about this condition and its natural history. In existing literature on MIS-C, there are currently no data about long-term outcomes. We report the case of a 14-year-old boy, with no significant past medical history, who presented a condition of multiorgan dysfunction due to MIS-C, after a SARS CoV-2 infection, and subsequent clinical-laboratory signs of hepatic steatosis at short-term follow-up. The case suggests how hepatic steatosis may be a possible sequela following SARS-CoV-2 infection, MIS-C and its medical treatment. Therefore, a close and long-term follow-up is needed to establish the pathophysiology and the evolution of this condition in patients following MIS-C.

show abstract

Short-Term Outcomes After Multisystem Inflammatory Syndrome in Children Treatment

Cited by 9 publications

References 9 publications

Abdominal US in Pediatric Inflammatory Multisystem Syndrome Associated with SARS-CoV-2 (PIMS-TS)

Abdominal US in Pediatric Inflammatory Multisystem Syndrome Associated with SARS-CoV-2 (PIMS-TS)

Cardiac manifestations in children with the multisystem inflammatory syndrome (MIS‐C) associated with SARS‐CoV‐2 infection: Systematic review and meta‐analysis

New Onset of Hepatic Steatosis Post-Severe Multisystem Inflammatory Syndrome in Children (MIS-C): A Case Report

Contact Info

Product

Resources

About